Androgen Receptor Expression in Relation to Apoptosis and the Expression of Cell Cycle Related Proteins in Prostate Cancer

Pathology and Oncology Research

Volumn 10, Issue 1, 2004, Pages 37-41

  Amirghofran, Zahra ^a   Monabati, Ahmad ^a   Gholijani, Naser ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Androgen receptor; Apoptosis; bax; bcl 2; Ki 67; p53; Prostate carcinoma

Indexed keywords

ANDROGEN RECEPTOR; CELL CYCLE PROTEIN; KI 67 ANTIGEN; PARAFFIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER STAGING; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HORMONE RECEPTOR INTERACTION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NICK END LABELING; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; SCORING SYSTEM; STAINING; STATISTICAL SIGNIFICANCE;

EID: 1942440451     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02893407     Document Type: Article

References (32)

1. Buttyan R, Shabsigh A, Perlman H, Colombel M. Regulation of Apoptosis in the Prostate Gland by Androgenic Steroids. Trends Endocrinol Metab 10: 47-54, 1999
2. Chang C, Saltzman A, Yeh S et al.: Androgen receptor: an overview. Crit Rev Eukaryot Gene Exp 5: 97-125, 1995
3. Eder IE, Culig Z, Putz T et al.: Molecular biology of the androgen receptor: from molecular understanding to the clinic. Eur Urol 40: 241-51, 2001
4. Klocker H, Culig Z, Eder IE et al: Mechanism of androgen receptor activation and possible implications for chemoprevention trials. Eur Urol 35: 413-419, 1999.
5. Kyprianou N, Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122: 552-562, 1988
6. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 20: 3001-3015, 2002
7. Feng Z, Joos HJ, Vallan C et al: Apoptosis during castration-induced regression of the prostate is Fos dependent. Oncogene 19: 17: 2593-600, 1998
8. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. J Urol 168: 9-12, 2002
9. Culig Z, Klocker H, Bartsch G et al: Androgen receptors in prostate cancer. J Urol 170: 1363-1369 2003.
10. Culig Z, Hobisch A, Erdel M et al: Studies on androgen receptor mutations and amplification in human prostatecancer. Methods Mol Med 81: 267-275, 2003
11. Sadi MV, Barrack ER: Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. Cancer 15: 71: 2574-2580, 1993
12. Miyamoto KK, McSherry SA, Dent GA et al.: Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue. J Urol 149: 1015-1019, 1993
13. de Winter JA, Trapman J, Brinkmann AO et al: Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry. J Pathol 160: 329-332, 1990
14. Shaffer DR, Scher HI. Prostate cancer: a dynamic illness with shifting targets. Lancet Oncol 4: 407-414, 2003
15. Magi-Galluzzi C, Xu X, Hlatky L et al: Heterogeneity of androgen receptor content in advanced prostate cancer. Mod Pathol 10: 839-845, 1997
16. Sweat SD, Pacelli A, Bergstralh EJ et al: Androgen receptor expression in prostatic intraepithelial neoplasia and cancer. J Urol 161: 1229-1232, 1999
17. Yoshikawa H, Ikeuchi T, Kai Y. Immunohistochemical study of androgen receptor in adenocarcinoma of the human prostatic cancer. Nippon Hinyokika Gakkai Zasshi 87: 956-963, 1996
18. van der Kwast TH, Schalken J, Ruizeveld de Winter JA et al: Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer 48: 189-193, 1991
19. Takeda H, Akakura K, Masai M et al.: Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer 77: 934-940, 1996
20. Finnegan NM, Curtin JF, Prevost G et al: Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions. Br J Cancer 85: 115-121, 2001
21. DiPaola RS, Aisner J. Overcoming bcl-2- and p53-mediated resistance in prostate cancer. Semin Oncol 26(Suppl) 2: 112-116, 1999
22. Kolar Z, Murray PG, Madarova J et al: Nuclear receptors in early hormone refractory prostate cancer and their relationship to apoptosis-related proteins. Neoplasma 49: 172-177, 2002
23. Fizazi K, Martinez LA, Sikes CR et al: The association of p21 (WAF-1/CIP1) with progression to androgen-independent prostate cancer. Clin Cancer Res 8: 775-781, 2002
24. Tanji N, Yokoyama M, Sagamoto T et al: Apoptosis in prostatic adenocarcinoma; A study of relationship to Ki-67 and bcl-2 protein expression. Anticancer Res 18: 1111-1116, 1998
25. Kaltz-Wittmer C, Klenk U, Glaessgen A et al: FISH analysis of gene aberrations (MYC, CCND1, ERBB2, RB, and AR) in advanced prostatic carcinomas before and after androgen deprivation therapy. Lab Invest 80: 1455-1464, 2000
26. Baretton GB, Klenk U, Diebold J et al: Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer 80: 546-555, 1999
27. Cadwell C, Zambetti GP: The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 17: 15-30, 2001
28. Brooks JD, Bova GS, Ewing CM et al: An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res 56: 3814-3822, 1996
29. Navone NM, Troncoso P, Pisters LL, et al.: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 85: 1657-1669, 1993
30. Aprikian AG, Sarkis AS, Fair WR et al: Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 151: 1276-1280, 1994
31. Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53. Curr Opin Oncol 14: 86-91, 2002
32. Howell SB. Resistance to apoptosis in prostate cancer cells. Mol Urol 4: 225-229, 2000